Recent advance in antiplatelet therapy: The mechanisms, evidence and approach to the problems

References

• Falk E., Shah P. K., Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657–71
   PubMed Web of Science ®Google Scholar
• Shah P. K. New insights into the pathogenesis and prevention of acute coronary syndromes. Am J Cardiol 1997; 79: 17–23
   Google Scholar
• Brass L. F. The molecular basis of platelet activation. Hematology: Basic Principles and Practice., R Hoffman, E. J Benz, Jr, S. J Shattil, B Furie, H. J Cohen, L. E Silberstein, , editors, et al. Elsevier, New York 2005; p. 1889–914, 4th ed
   Google Scholar
• Plow E. F., Ginsberg M. H. The molecular basis for platelet funcion. Hematology: Basic Principles and Practice., R Hoffman, E. J Benz, Jr, S. J Shattil, B Furie, H. J Cohen, L. E Silberstein, , editors, et al. Elsevier, New York 2005; p. 1881–97, 4th ed
   Google Scholar
• Fuster V., Moreno P. R., Fayad Z. A., Corti R., Badimon J. J. Atherothrombosis and high‐risk plaque: part I: evolving concepts. J Am Coll Cardiol 2005; 46: 937–54
   PubMed Web of Science ®Google Scholar
• Coughlin S. R. Thrombin signalling and protease‐activated receptors. Nature 2000; 407: 258–64
   PubMed Web of Science ®Google Scholar
• Knight D. E., Hallam T. J., Scrutton M. C. Agonist selectivity and second messenger concentration in Ca2+‐mediated secretion. Nature 1982; 296: 256–7
   PubMed Web of Science ®Google Scholar
• Hirata T., Ushikubi F., Kakizuka A., Okuma M., Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 1996; 97: 949–56
   PubMed Web of Science ®Google Scholar
• Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287–94
   PubMed Web of Science ®Google Scholar
• Bhatt D. L., Topol E. J. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003; 2: 15–28
   PubMed Web of Science ®Google Scholar
• Chandrasekharan N. V., Dai H., Roos K. L., Evanson N. K., Tomsik J., Elton T. S., et al. COX‐3, a cyclooxygenase‐1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99: 13926–31
   PubMed Web of Science ®Google Scholar
• Dogne J. M., Hanson J., Pratico D. Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. Trends Pharmacol Sci 2005; 26: 639–44
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists' Colloboration. Collaborative meta‐analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86
   Google Scholar
• Grotemeyer K. H., Scharafinski H. W., Husstedt I. W. Two‐year follow‐up of aspirin responder and aspirin non responder. A pilot‐study including 180 post‐stroke patients. Thromb Res 1993; 71: 397–403
   PubMed Web of Science ®Google Scholar
• Mueller M. R., Salat A., Stangl P., Murabito M., Pulaki S., Boehm D., et al. Variable platelet response to low‐dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003–7
   PubMed Web of Science ®Google Scholar
• Grundmann K., Jaschonek K., Kleine B., Dichgans J., Topka H. Aspirin non‐responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003; 250: 63–6
   PubMed Web of Science ®Google Scholar
• Eikelboom J. W., Hankey G. J. Aspirin resistance: a new independent predictor of vascular events?. J Am Coll Cardiol 2003; 41: 966–8
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980–7
   PubMed Web of Science ®Google Scholar
• Sztriha L. K., Sas K., Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci 2005; 229–30: 163–9
   Google Scholar
• Michelson A. D., Cattaneo M., Eikelboom J. W., Gurbel P., Kottke‐Marchant K., Kunicki T. J., et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005; 3: 1309–11
   PubMed Web of Science ®Google Scholar
• Born G. V., Haslam R. J., Goldman M. Comparative Effectiveness of Adenosine Analogues as Inhibitors of Blood‐Platelet Aggregation and as Vasodilators in Man. Nature 1965; 205: 678–80
   PubMed Web of Science ®Google Scholar
• Gum P. A., Kottke‐Marchant K., Welsh P. A., White J., Topol E. J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961–5
   PubMed Web of Science ®Google Scholar
• Valles J., Santos M. T., Aznar J., Osa A., Lago A., Cosin J., et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low‐dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998; 97: 350–5
   PubMed Web of Science ®Google Scholar
• Zimmermann N., Wenk A., Kim U., Kienzle P., Weber A. A., Gams E., et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542–7
   PubMed Web of Science ®Google Scholar
• Chen W. H., Lee P. Y., Ng W., Tse H. F., Lau C. P. Aspirin resistance is associated with a high incidence of myonecrosis after non‐urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122–6
   PubMed Web of Science ®Google Scholar
• Eikelboom J. W., Hirsh J., Weitz J. I., Johnston M., Yi Q., Yusuf S. Aspirin‐resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650–5
   PubMed Web of Science ®Google Scholar
• Gonzalez‐Conejero R., Rivera J., Corral J., Acuna C., Guerrero J. A., Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure?. Stroke 2005; 36: 276–80
   PubMed Web of Science ®Google Scholar
• Nicholson N. S., Panzer‐Knodle S. G., Haas N. F., Taite B. B., Szalony J. A., Page J. D., et al. Assessment of platelet function assays. Am Heart J 1998; 135: S170–8
   PubMed Web of Science ®Google Scholar
• Catella‐Lawson F., Reilly M. P., Kapoor S. C., Cucchiara A. J., DeMarco S., Tournier B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809–17
   PubMed Web of Science ®Google Scholar
• MacDonald T. M., Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573–4
   PubMed Web of Science ®Google Scholar
• Kurth T., Glynn R. J., Walker A. M., Chan K. A., Buring J. E., Hennekens C. H., et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003; 108: 1191–5
   PubMed Web of Science ®Google Scholar
• Berglund U., Wallentin L. Persistent inhibition of platelet function during long‐term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease. Eur Heart J 1991; 12: 428–33
   PubMed Web of Science ®Google Scholar
• Pulcinelli F. M., Pignatelli P., Celestini A., Riondino S., Gazzaniga P. P., Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long‐term treated patients. J Am Coll Cardiol 2004; 43: 979–84
   PubMed Web of Science ®Google Scholar
• Friend M., Vucenik I., Miller M. Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia. BMJ 2003; 326: 82–3
   PubMed Web of Science ®Google Scholar
• Larsson P. T., Wallen N. H., Hjemdahl P. Norepinephrine‐induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation 1994; 89: 1951–7
   PubMed Web of Science ®Google Scholar
• Hung J., Lam J. Y., Lacoste L., Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation 1995; 92: 2432–6
   PubMed Web of Science ®Google Scholar
• Halushka M. K., Halushka P. V. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2?. Circulation 2002; 105: 1620–2
   Web of Science ®Google Scholar
• Cambria‐Kiely J. A., Gandhi P. J. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2002; 14: 51–8
   PubMedGoogle Scholar
• Kunapuli S. P., Dorsam R. T., Kim S., Quinton T. M. Platelet purinergic receptors. Curr Opin Pharmacol 2003; 3: 175–80
   PubMed Web of Science ®Google Scholar
• Dorsam R. T., Kunapuli S. P. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113: 340–5
   PubMed Web of Science ®Google Scholar
• Jin J., Daniel J. L., Kunapuli S. P. Molecular basis for ADP‐induced platelet activation. II. The P2Y1 receptor mediates ADP‐induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 2030–4
   PubMed Web of Science ®Google Scholar
• Goto S., Tamura N., Eto K., Ikeda Y., Handa S. Functional significance of adenosine 5'‐diphosphate receptor (P2Y(12)) in platelet activation initiated by binding of von Willebrand factor to platelet GP Ibalpha induced by conditions of high shear rate. Circulation 2002; 105: 2531–6
   PubMed Web of Science ®Google Scholar
• Remijn J. A., Wu Y. P., Jeninga E. H., IJsseldijk M. J., van Willigen G., de Groot P. G., et al. Role of ADP receptor P2Y(12) in platelet adhesion and thrombus formation in flowing blood. Arterioscler Thromb Vasc Biol 2002; 22: 686–91
   PubMed Web of Science ®Google Scholar
• van Gestel M. A., Heemskerk J. W., Slaaf D. W., Heijnen V. V., Reneman R. S., oude Egbrink M. G. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler Thromb Vasc Biol 2003; 23: 518–23
   PubMed Web of Science ®Google Scholar
• Hass W. K., Easton J. D., Adams H. P., Jr., Pryse‐Phillips W., Molony B. A., Anderson S., et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high‐risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501–7
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–39
   PubMed Web of Science ®Google Scholar
• Yusuf S., Zhao F., Mehta S. R., Chrolavicius S., Tognoni G., Fox K. K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Engl J Med 2001; 345: 494–502
   PubMed Web of Science ®Google Scholar
• Moake J. L. Thrombotic thrombocytopenic purpura: the systemic clumping “plague”. Annu Rev Med 2002; 53: 75–88
   PubMed Web of Science ®Google Scholar
• Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171–5
   PubMed Web of Science ®Google Scholar
• Lau W. C., Gurbel P. A., Watkins P. B., Neer C. J., Hopp A. S., Carville D. G., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166–71
   PubMed Web of Science ®Google Scholar
• Narumiya S., Sugimoto Y., Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79: 1193–226
   PubMed Web of Science ®Google Scholar
• Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425–36
   PubMed Web of Science ®Google Scholar
• Dusting G. J., Moncada S., Vane J. R. Recirculation of prostacyclin (PGI2) in the dog. Br J Pharmacol 1978; 64: 315–20
   PubMed Web of Science ®Google Scholar
• Demolis J. L., Robert A., Mouren M., Funck‐Brentano C., Jaillon P. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J Cardiovasc Pharmacol 1993; 22: 711–6
   PubMed Web of Science ®Google Scholar
• Lievre M., Morand S., Besse B., Fiessinger J. N., Boissel J. P. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double‐blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. Circulation 2000; 102: 426–31
   PubMed Web of Science ®Google Scholar
• Mohler E. R 3rd., Hiatt W. R., Olin J. W., Wade M., Jeffs R., Hirsch A. T. Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double‐blinded, randomized, controlled trial. J Am Coll Cardiol 2003; 41: 1679–86
   PubMed Web of Science ®Google Scholar
• Origasa H., Ikeda Y., Shimada K., Shigematsu H. Oral Beraprost Sodium as a Prostaglandin I2 Analogue for Vascular Events in patients with Peripheral Arterial Disease: Meta‐Analysis of Two Placebo‐Controlled Randomized Trials. Jpn J Pharmacoepidemiol 2004; 9: 45–51
   Google Scholar
• Haslam R. J., Dickinson N. T., Jang E. K. Cyclic nucleotides and phosphodiesterases in platelets. Thromb Haemost 1999; 82: 412–23
   PubMed Web of Science ®Google Scholar
• Geiger J., Teichmann L., Grossmann R., Aktas B., Steigerwald U., Walter U., et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005; 51: 957–65
   PubMed Web of Science ®Google Scholar
• Sudo T., Tachibana K., Toga K., Tochizawa S., Inoue Y., Kimura Y., et al. Potent effects of novel anti‐platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000; 59347–56
   Google Scholar
• Goto S. Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005; Nov 3, [Epub ahead of print]
   Google Scholar
• Money S. R., Herd J. A., Isaacsohn J. L., Davidson M., Cutler B., Heckman J., et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27: 267–74
   PubMed Web of Science ®Google Scholar
• Dawson D. L., Cutler B. S., Meissner M. H., Strandness D. E., Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double‐blind trial. Circulation 1998; 98: 678–86
   PubMed Web of Science ®Google Scholar
• Dormandy J. A., Rutherford R. B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter‐Society Concensus (TASC). J Vasc Surg 2000; 31: S1–S296
   Google Scholar
• Gotoh F., Tohgi H., Hirai S., Terashi A., Fukuuchi Y., Otomo E., et al. Cirostazol Stroke Prevention Study: A placebo‐controlled double‐blinded trial for secondary prevention of cerebral infarction. Journal of Stroke and Cerebrovascular Diseases 2000; 9: 147–57
   PubMedGoogle Scholar
• Sakuma I., Akaishi Y., Fukao M., Makita Y., Makita M. A., Kobayashi T., et al. Dipyridamole potentiates the anti‐aggregating effect of endothelium‐derived relaxing factor. Thromb Res Suppl 1990; 12: 87–90
   Google Scholar
• Diener H. C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13
   PubMed Web of Science ®Google Scholar
• De Schryver E. L., Algra A., van Gijn J. Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 2003; 34: 2072–80
   PubMed Web of Science ®Google Scholar
• Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Lancet 1999; 354: 447–55
   PubMed Web of Science ®Google Scholar
• Yokoyama M. Effects of eicosapentaenoic acid (EPA) on major cardiovascular events in hypercholesterolemic patients: the Japan EPA Lipid Intervention Study (JELIS) Circulation. 2005; 112: 3362–3
   Google Scholar
• Kris‐Etherton P. M., Harris W. S., Appel L. J. Fish consumption, fish oil, omega‐3 fatty acids, and cardiovascular disease. Circulation 2002; 106: 2747–57
   PubMed Web of Science ®Google Scholar
• Needleman P., Raz A., Minkes M. S., Ferrendelli J. A., Sprecher H. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci U S A 1979; 76: 944–8
   PubMed Web of Science ®Google Scholar
• Tyce G. M. Origin and metabolism of serotonin. J Cardiovasc Pharmacol 1990; 16((Suppl 3))S1–7
   PubMedGoogle Scholar
• Vanhoutte P. M. Platelet‐derived serotonin, the endothelium, and cardiovascular disease. J Cardiovasc Pharmacol 1991; 17((Suppl 5))S6–12
   Google Scholar
• Trubestein G., Bohme H., Heidrich H., Heinrich F., Hirche H., Maass U., et al. Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study. Angiology 1984; 35: 701–8
   Google Scholar
• Adhoute G., Bacourt F., Barral M., Cardon J. M., Chevalier J. M., Cuny A., et al. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg. Angiology 1986; 37: 160–7
   PubMed Web of Science ®Google Scholar
• Doggrell S. A. Sarpogrelate: cardiovascular and renal clinical potential. Expert Opin Investig Drugs 2004; 13: 865–74
   PubMed Web of Science ®Google Scholar
• Bhatt D. L., Topol E. J. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000; 284: 1549–58
   PubMed Web of Science ®Google Scholar
• O'Shea J. C., Hafley G. E., Greenberg S., Hasselblad V., Lorenz T. J., Kitt M. M., et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001; 285: 2468–73
   PubMed Web of Science ®Google Scholar
• Topol E. J., Moliterno D. J., Herrmann H. C., Powers E. R., Grines C. L., Cohen D. J., et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888–94
   PubMed Web of Science ®Google Scholar
• Quinn M. J., Plow E. F., Topol E. J. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two‐edged sword?. Circulation 2002; 106: 379–85
   PubMed Web of Science ®Google Scholar
• Quinn M. J., Byzova T. V., Qin J., Topol E. J., Plow E. F. Integrin alphaIIbbeta3 and its antagonism. Arterioscler Thromb Vasc Biol 2003; 23: 945–52
   PubMed Web of Science ®Google Scholar
• Cox D., Smith R., Quinn M., Theroux P., Crean P., Fitzgerald D. J. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1514–9
   PubMed Web of Science ®Google Scholar